TCGA-CQ-6221-01A-11R-2081-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- ANGIOGENESIS+0.400
- PANCREAS_BETA_CELLS+0.360
- UV_RESPONSE_DN+0.250
- COAGULATION+0.210
- PROTEIN_SECRETION+0.200
- IL6_JAK_STAT3_SIGNALING+0.160
- COMPLEMENT+0.070
- KRAS_SIGNALING_UP+0.070
- MYOGENESIS+0.060
Top 10 suppressed
- MYC_TARGETS_V2-0.470
- E2F_TARGETS-0.420
- G2M_CHECKPOINT-0.410
- MYC_TARGETS_V1-0.410
- INTERFERON_ALPHA_RESPONSE-0.360
- P53_PATHWAY-0.360
- MTORC1_SIGNALING-0.350
- ESTROGEN_RESPONSE_LATE-0.330
- MITOTIC_SPINDLE-0.310
- CHOLESTEROL_HOMEOSTASIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-IQ-A61O-01A-11R-A30B-07 | — | — | 0.884 |
| 2 | SRR8518451 | — | A | 0.842 |
| 3 | SRR12475118 | — | — | 0.833 |
| 4 | MBCProject_1493_T1_RNA | — | A | 0.811 |
| 5 | TCGA-55-8096-01A-11R-2241-07 | — | cohortA1 | 0.799 |
| 6 | 632ac2fc-e387-461f-97e2-bc72b1c9ffe4 | — | — | 0.783 |
| 7 | SRR25617871 | — | C | 0.778 |
| 8 | ERR2278848 | — | — | 0.777 |
| 9 | TCGA-44-2665-01A-01R-0946-07 | — | cohortA1 | 0.774 |
| 10 | 09552358-6d23-4990-858e-908ee5a132f6 | — | — | 0.773 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| COMPLEMENT | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.070 | Inavolisib | — uncovered |
| MYOGENESIS | 0.060 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.060 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.050 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.030 | Inavolisib | — uncovered |